Charles Fuchs, MD: Percentage of RAS Mutation Tests in Metastatic CRC

A phase 2/3 study of GRANITE vaccine in combination with standard therapy shows encouraging early signs of efficacy and safety in patients with metastatic microsatellite-stable colorectal cancer.

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

For Colorectal Cancer Awareness Month, Jedrzej Wykretowicz, MD, PhD, discussed the importance of early detection and taking steps towards the prevention of colorectal cancer.

In season 2, episode 6 of Targeted Talks, Dr. Michael J. Overman, joins Targeted Oncology for a special discussion around rare genomic alterations in colorectal cancer

In an interview with Targeted Oncology, Andreana N. Holowatyj, PhD, MSCI, discussed data from a study which found racial and ethnic differences in susceptibility genes for early-onset colorectal cancer, suggesting current multigene panel tests may not be accurate for diverse populations.

Adagrasib plus cetuximab as a potential treatment option addresses an unmet need in pretreated KRAS G12C-mutated colorectal cancer, offering hope for improved outcomes.